Viking Therapeutics Inc (VKTX)
74.31
+5.45
(+7.91%)
USD |
NASDAQ |
Apr 26, 16:00
74.69
+0.38
(+0.51%)
After-Hours: 20:00
Viking Therapeutics Enterprise Value: 7.231B for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 26, 2024 | 7.231B |
| April 25, 2024 | 6.630B |
| April 24, 2024 | 6.212B |
| April 23, 2024 | 6.197B |
| April 22, 2024 | 6.078B |
| April 19, 2024 | 6.030B |
| April 18, 2024 | 6.168B |
| April 17, 2024 | 6.367B |
| April 16, 2024 | 6.530B |
| April 15, 2024 | 6.419B |
| April 12, 2024 | 6.601B |
| April 11, 2024 | 6.849B |
| April 10, 2024 | 6.935B |
| April 09, 2024 | 7.065B |
| April 08, 2024 | 7.401B |
| April 05, 2024 | 7.464B |
| April 04, 2024 | 7.159B |
| April 03, 2024 | 7.683B |
| April 02, 2024 | 7.563B |
| April 01, 2024 | 7.800B |
| March 28, 2024 | 8.676B |
| March 27, 2024 | 8.811B |
| March 26, 2024 | 8.535B |
| March 25, 2024 | 7.254B |
| March 22, 2024 | 7.293B |
| Date | Value |
|---|---|
| March 21, 2024 | 7.408B |
| March 20, 2024 | 7.457B |
| March 19, 2024 | 6.812B |
| March 18, 2024 | 6.611B |
| March 15, 2024 | 6.524B |
| March 14, 2024 | 6.752B |
| March 13, 2024 | 7.507B |
| March 12, 2024 | 6.976B |
| March 11, 2024 | 6.575B |
| March 08, 2024 | 7.488B |
| March 07, 2024 | 7.730B |
| March 06, 2024 | 9.609B |
| March 05, 2024 | 9.250B |
| March 04, 2024 | 9.627B |
| March 01, 2024 | 8.323B |
| February 29, 2024 | 7.490B |
| February 28, 2024 | 9.269B |
| February 27, 2024 | 8.306B |
| February 26, 2024 | 3.505B |
| February 23, 2024 | 3.398B |
| February 22, 2024 | 3.221B |
| February 21, 2024 | 3.173B |
| February 20, 2024 | 3.229B |
| February 16, 2024 | 3.276B |
| February 15, 2024 | 2.838B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-25.30M
Minimum
Mar 16 2020
9.627B
Maximum
Mar 04 2024
686.24M
Average
241.54M
Median
Oct 26 2021
Enterprise Value Benchmarks
| Eli Lilly and Co | 719.79B |
| Pfizer Inc | 201.86B |
| Madrigal Pharmaceuticals Inc | 3.328B |
| Akero Therapeutics Inc | 835.98M |
| Terns Pharmaceuticals Inc | 54.00M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.36M |
| Total Expenses (Quarterly) | 34.07M |
| EPS Diluted (Quarterly) | -0.26 |
| Earnings Yield | -1.25% |